相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Convergence-Based Framework for Cancer Drug Resistance
David J. Konieczkowski et al.
CANCER CELL (2018)
Improving combination cancer therapy: the CombiPlex((R)) development platform
Anthony W. Tolcher et al.
FUTURE ONCOLOGY (2018)
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
Douae Bensaid et al.
CLINICAL EPIGENETICS (2018)
Rationalizing combination therapies
[Anonymous]
NATURE MEDICINE (2017)
DNA methylation at enhancers identifies distinct breast cancer lineages
Thomas Fleischer et al.
NATURE COMMUNICATIONS (2017)
Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma
Yaqin Zhang et al.
CELL AND BIOSCIENCE (2017)
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Sergey Karakashev et al.
CELL REPORTS (2017)
Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer
Ravi Doddapaneni et al.
SCIENTIFIC REPORTS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments
Mechthild Krause et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Dmitri Pchejetski et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells
Karolina Lapinska et al.
ANTICANCER RESEARCH (2016)
Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth
Rajneesh Pathania et al.
CANCER RESEARCH (2016)
Two is better than one; toward a rational design of combinatorial therapy
Sheng-hong Chen et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2016)
A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis
Mckenna Longacre et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Tissue-specific mutation accumulation in human adult stem cells during life
Francis Blokzijl et al.
NATURE (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
The Evolution of Epigenetics: From Prokaryotes to Humans and Its Biological Consequences
Amber Willbanks et al.
GENETICS & EPIGENETICS (2016)
Chromosomal Loop Domains Direct the Recombination of Antigen Receptor Genes
Jiazhi Hu et al.
CELL (2015)
Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer
Anand Kamal Singh et al.
CLINICAL CANCER RESEARCH (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Ana Bosch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
EMT and tumor metastasis
Sarah Heerboth et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2015)
DNMT3A in haematological malignancies
Liubin Yang et al.
NATURE REVIEWS CANCER (2015)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Michela Tassara et al.
BLOOD (2014)
New Strategies in Lung Cancer: Epigenetic Therapy for Non-Small Cell Lung Cancer
Patrick M. Forde et al.
CLINICAL CANCER RESEARCH (2014)
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Hariharan Easwaran et al.
MOLECULAR CELL (2014)
Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance
Ercan Cacan et al.
PLOS ONE (2014)
Do epigenetic drug treatments hold the key to killing cancer progenitor cells?
Shannon Byler et al.
EPIGENOMICS (2014)
HDAC inhibitors and immunotherapy; a double edged sword?
Michiel Kroesen et al.
ONCOTARGET (2014)
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Daniela Luvero et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Cancer Development, Progression, and Therapy: An Epigenetic Overview
Sibaji Sarkar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Byram W. Bridle et al.
MOLECULAR THERAPY (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
Cristian Tomasetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Oncogenic Driver Mutations: Neither Tissue-Specific nor Independent
A. A. Margolin
Science Translational Medicine (2013)
Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy
Sibaji Sarkar et al.
EPIGENOMICS (2013)
Telomere-Homologous G-Rich Oligonucleotides Sensitize Human Ovarian Cancer Cells to TRAIL-Induced Growth Inhibition and Apoptosis
Sibaji Sarkar et al.
NUCLEIC ACID THERAPEUTICS (2013)
Mechanisms and insights into drug resistance in cancer
Hiba Zahreddine et al.
FRONTIERS IN PHARMACOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Alexa B. Turke et al.
CANCER RESEARCH (2012)
Therapeutic strategies in epithelial ovarian cancer
Ayako Kim et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Swen Hoelder et al.
MOLECULAR ONCOLOGY (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
A Blueprint for Advancing Genetics-Based Cancer Therapy
William R. Sellers
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
T-Oligos Inhibit Growth and Induce Apoptosis in Human Ovarian Cancer Cells
Sibaji Sarkar et al.
OLIGONUCLEOTIDES (2011)
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Christine L. Chaffer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
Gina Mantia-Smaldone et al.
Cancer Management and Research (2011)
Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells
Anne-Sophie Belanger et al.
BMC MOLECULAR BIOLOGY (2010)
Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K
P. Maier et al.
GENE THERAPY (2010)
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells
Nish Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
David Lesniak et al.
CANCER RESEARCH (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
Bahriye Aktas et al.
BREAST CANCER RESEARCH (2009)
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells
Bryan C. Fuchs et al.
CANCER RESEARCH (2008)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
Kathy S. Albain et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J. Frew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
L. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
Hongwu Shen et al.
DRUG METABOLISM AND DISPOSITION (2007)
DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia
Shuchi Agrawal et al.
CANCER RESEARCH (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Mechanisms of disease - Cancer stem cells
Craig T. Jordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
D Sampath et al.
BLOOD (2006)
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer
JF Gagnon et al.
CLINICAL CANCER RESEARCH (2006)
Cytochrome P450 pharmacogenetics and cancer
C Rodriguez-Antona et al.
ONCOGENE (2006)
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination moth all-trans retinoic acid in patients with acute myeloid leukemia
A Kuendgen et al.
CANCER (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Tumoral drug metabolism: Overview and its implications for cancer therapy
M Michael et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
A Kuendgen et al.
BLOOD (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
The role of glutathione-S-transferase in anti-cancer drug resistance
DM Townsend et al.
ONCOGENE (2003)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
M Jain et al.
SCIENCE (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde
JP Plastaras et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
